User profiles for ANDREAS D. HARTKOPF
Andreas D. HartkopfDepartment of Women's Health, Tuebingen University Verified email at med.uni-tuebingen.de Cited by 5637 |
Early dissemination seeds metastasis in breast cancer
…, M Grauvogl, N Eichner, F Weber, AD Hartkopf… - Nature, 2016 - nature.com
Accumulating data suggest that metastatic dissemination often occurs early during tumour
formation, but the mechanisms of early metastatic spread have not yet been addressed. Here, …
formation, but the mechanisms of early metastatic spread have not yet been addressed. Here, …
Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer
Importance Cytotoxic CD8 + tumor-infiltrating lymphocytes (TILs) participate in immune control
of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8 + …
of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8 + …
[HTML][HTML] Mutations in BRCA1/2 and other panel genes in patients with metastatic breast cancer—Association with patient and disease characteristics and effect on …
PURPOSE Among patients with metastatic breast cancer (mBC), the frequency of germline
mutations in cancer susceptibility genes and the clinical relevance of these mutations are …
mutations in cancer susceptibility genes and the clinical relevance of these mutations are …
[HTML][HTML] Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
A Hein, AD Hartkopf, J Emons, MP Lux, B Volz… - European journal of …, 2021 - Elsevier
… - original draft, review & editing, supervision, visualisation and project administration; Andreas
D. Hartkopf helped in resources, project administration, review & editing and investigation; …
D. Hartkopf helped in resources, project administration, review & editing and investigation; …
Endocrine-resistant breast cancer: mechanisms and treatment
AD Hartkopf, EM Grischke, SY Brucker - Breast care, 2020 - karger.com
Background: Endocrine treatment is one of the most effective therapies for estrogen receptor-positive
breast cancer. However, most tumors will develop resistance to endocrine therapy …
breast cancer. However, most tumors will develop resistance to endocrine therapy …
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry
V Müller, N Nabieva, L Häberle, FA Taran, AD Hartkopf… - The Breast, 2018 - Elsevier
Objectives Improved progression-free survival is considered as treatment goal for patients
with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of …
with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of …
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
We aimed to validate the prognostic association of p16 expression in ovarian high‐grade
serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein …
serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein …
[HTML][HTML] Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients–results from a large single-centre analysis
AD Hartkopf, FA Taran, M Wallwiener, M Hahn… - European journal of …, 2014 - Elsevier
Background This is the largest single-centre study to determine the prognostic relevance of
disseminated tumour cells (DTCs) from the bone marrow (BM) of stage I-III breast cancer …
disseminated tumour cells (DTCs) from the bone marrow (BM) of stage I-III breast cancer …
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors–Data from the German PRAEGNANT breast cancer …
AD Hartkopf, J Huober, B Volz, N Nabieva, FA Taran… - The Breast, 2018 - Elsevier
Purpose This study describes comprehensive data from a breast cancer registry concerning
the use of endocrine treatment (ET) and chemotherapy in the first, second and higher …
the use of endocrine treatment (ET) and chemotherapy in the first, second and higher …
Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer
AD Hartkopf, P Wagner, D Wallwiener… - Anticancer …, 2011 - ar.iiarjournals.org
Background: The detection of >5 circulating tumor cells (CTCs)/7.5 ml blood in patients being
treated for metastatic breast cancer (MBC) has recently been shown to be predictive for …
treated for metastatic breast cancer (MBC) has recently been shown to be predictive for …